AVITA Medical, Inc.

AVITA Medical is a medical technology company that develops and commercializes regenerative therapeutics for acute wound care. Its primary product is the RECELL system, a point-of-care autologous cell harvesting device that processes a small donor skin sample into a cellular suspension to treat thermal burns and full-thickness skin defects. The company also offers PermeaDerm, a biosynthetic wound matrix that provides protective coverage, and Cohealyx, a collagen-based dermal matrix designed for wound bed preparation. Its commercial products primarily serve surgeons, clinicians, acute care hospitals, specialized burn centers, and trauma centers treating complex surgical and traumatic injuries.

The company operates in the United States and employs approximately 226 workers, with most staff based domestically. It maintains manufacturing, assembly, and warehousing operations at an FDA-registered facility in Ventura, California, alongside administrative and research offices in Valencia and Irvine, California. Outside the United States, the company distributes products through third-party partners across international markets where it holds regulatory authorizations, including Australia, Japan, and Europe.

Summary of the business section of AVITA Medical's latest annual report, written by StockData.

“As of December 31, 2025, we employed approximately 226 full-time and part-time employees, the majority of whom are based in the U.S.”